About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- Coronavirus could spark a 20% tech pullback, investor Paul Meeks warns
- Coronavirus live updates: Austria halts train traffic with Italy, Turkey closes Iran border
- Here's how NFL TV rights are expected to shake out for the rest of the decade, according to sources
- Buttigieg campaign calls on Nevada Democrats to address alleged irregularities in caucuses
- Bernie Sanders will win the Nevada caucus, NBC News projects, cementing his front-runner status
NBR on TwitterMy Tweets
Subscribe to RSS
Endo International will buy Par Pharmaceuticals for $8 billion, which will make Endo a bigger player in the fast-changing generic drug sector.
Telecom giant Verizon announced Tuesday it will be buying AOL for $50 per share, or about $4.4 billion. (Tweet This) AOL’s stock was up more than 17 percent after the announcement. Verizon’s stock was down slightly. AOL co-founder Steve Case tweeted his approval. The transaction will be completed this summer and will take the form …
Microsoft is reportedly thinking about buying Salesforce, but why would it want to?
Comcast Chairman and CEO Brian Roberts said Friday the media giant had made good case for its proposed acquisition of Time Warner Cable. In the end, however it’s “time to move on,” he said. Roberts appeared on CNBC shortly after Comcast called off its plans to acquire Time Warner Cable amid opposition from regulators, particularly …
The red hot market for big pharma deals just got hotter as Teva launched a hostile $40 billion bid for Mylan.
What happens next to the proposed cable TV mega merger as executives from Comcast and Time Warner Cable meet with regulators? Julia Boorstin reports.
Royal Dutch Shell will buy BG Group for $70 billion. Jackie DeAngelis explains what the deal could mean for the industry.
Royal Dutch Shell‘s £47 billion ($69 billion) agreed deal for energy company BG Group has already created turmoil. Shares in the UK energy utility soared nearly 40 percent, sending the entire London market higher on Wednesday. Meanwhile, Shell’s own share price was down around 3 percent, reflecting concerns about the execution of the deal. Shell’s …
FedEx will buy Europe’s TNT Express for nearly $5 billion in an effort to expand into Europe.
Kraft Foods Group stock surged Wednesday after the company announced a merger deal with H.J. Heinz financed in part by Warren Buffett. Buffett told CNBC that his Berkshire Hathaway company will have $9.5 billion worth of common stock in the newly merged H.J. Heinz-Kraft Foods company. It will be headed by Heinz Chief Executive Bernardo …
You know who’s not at all worried about the Expedia-Orbitz tie-up?Priceline investors. Shares of Priceline have climbed 4.1 percent in the two trading days since Expedia’s $1.6 billion acquisition of Orbitz was announced Thursday morning. Expedia shares are up even more, jumping 14 percent. While on paper the combination of Expedia and Orbitz creates a …
Expedia will buy rival Orbitz for $1.6 billion. Simon Hobbs takes a look at how the deal could change the global online travel industry.
Mergers and acquisitions experts forecast there will be more major pharmaceutical deals in 2015, but it won’t be a repeat of last year’s frenzy: The U.K. won’t be a focus and deals won’t be done for tax reasons. “Running into 2015, I am expecting to see a lot more pharma M&A,” said Hamilton Matthews, CEO …
Drug giant Merck said it will buy Cubist Pharmaceuticals for about $9.5 billion, or $102 a share in cash, bringing Merck a slate of medicines administered in the hospital setting, many for bacterial infections. News of the deal sent Cubist’s share price surging by more than 34 percent, to $101.15, in premarket trading. Merck’s stock …
Actavis announced on Monday that it will acquire Allergan for $66 billion, or $219 per share in cash and Actavis shares. “Today’s transaction provides Allergan stockholders with substantial and immediate value, as well as the opportunity to participate in the significant upside potential of the combined company,” David E. I. Pyott, chairman and CEO of …